Peregrine Pharmaceuticals Reports Financial Results for Fiscal...(---- ---- ASSETS CURREN ...),Health

Date:7/14/2009

---- ---- ASSETS CURRENT ASSETS: Cash and cash equivalents $10,018,000 $15,130,000 Trade and other receivables 1,770,000 605,000 Government contract receivables 1,944,000 - Inventories, net 4,707,000 2,900,000 Debt issuance costs, current portion 229,000 - Prepaid expenses and other current assets, net 1,466,000 1,208,000 --------- --------- Total current assets 20,134,000 19,843,000 PROPERTY: Leasehold improvements 675,000 669,000 Laboratory equipment 4,180,000 4,140,000 Furniture, fixtures and computer equipment 902,000 919,000 ------- ------- 5,757,000 5,728,000 Less accumulated depreciation and amortization (4,076,000) (3,670,000) ---------- ---------- Property, net 1,681,000 2,058,000 Debt issuance costs, less current portion 142,000 - Other assets 1,170,000 1,156,000 --------- --------- TOTAL ASSETS $23,127,000 $23,057,000 =========== ===========

    PEREGRINE PHARMACEUTICALS, INC.

    CONSOLIDATED BALANCE SHEETS
    AS OF APRIL 30, 2009 AND 2008 (continued)

                                                        2009          2008
                                                
'/>"/>
SOURCE  Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer